Anti-inflammatory Activity of a Pteridine Derivative (4AZA2096) Alleviates TNBS-Induced Colitis in Mice
Authors:
- 1 August 2006
- journal article
- research article
- Published by SAGE Publications in Journal of Interferon & Cytokine Research
- Vol. 26 (8) , 575-582
Abstract
Elevated production of tumor necrosis factor (TNF) plays a central role in the pathogenesis of many inflammatory diseases, such as rheumatoid arthritis and Crohn's disease. Naturally occurring pteridine analogs have been reported to have potent immunomodulatory activity, especially on TNF production. The aim of this study is to identify small molecule TNF inhibitiors derived from pteridine and to prove their in vivo efficacy in an inflammatory model. A focused chemical library based on the pteridine scaffold was screened in vitro on lipopolysaccharide (LPS)-induced TNF production in peripheral blood mononuclear cells (PBMC). One synthetic pteridine analog (4AZA2096), shown to have strong inhibitory activity, was selected and tested for its efficacy to treat trinitrobenzenesulfonate (TNBS)-induced colitis in mice, a model of Crohn's disease. Colitis was induced by rectal administration of 1 mg TNBS in 50% ethanol after presensitization via the skin. The synthetic pteridine analog 4AZA2096 was shown to potently inhibit LPS-induced TNF production in vitro. Colitic mice treated with 4AZA2096 orally (20 mg/kg/day) recovered more rapidly and, histologically, had a reduction of inflammatory lesions, less edema, a reduction of goblet cell loss, and reduced wall thickness. Cell infiltration in the colon, especially infiltration of neutrophils, as shown by myeloperoxidase (MPO) activity, was reduced in 4AZA2096-treated animals. Intralesional TNF production was lower in mice of the treated groups, whereas interleukin-18 (IL-18) and interferon-γ (IFN-γ) mRNA were not affected. Treatment had no effect on anti-TNBS antibody production, arguing against generalized immunosuppression. In conclusion, we identified a pteridine derivative, 4AZA2096, with strong inhibitory activity on TNF production and a remission- inducing effect in TNBS colitis, supporting further preclinical and clinical development of this novel TNF inhibitor for treatment of inflammatory diseases.Keywords
This publication has 30 references indexed in Scilit:
- Using genome-wide transcriptional profiling to elucidate small-molecule mechanismCurrent Opinion in Chemical Biology, 2005
- Rapid Structure-Activity and Selectivity Analysis of Kinase Inhibitors by BioMAP Analysis in Complex Human Primary Cell-Based ModelsASSAY and Drug Development Technologies, 2004
- Target validationCurrent Opinion in Pharmacology, 2003
- The Immunology of Mucosal Models of InflammationAnnual Review of Immunology, 2002
- B7h, a Novel Costimulatory Homolog of B7.1 and B7.2, Is Induced by TNFαImmunity, 1999
- Impaired On/Off Regulation of TNF Biosynthesis in Mice Lacking TNF AU-Rich ElementsImmunity, 1999
- TNF-α Induction of CD44-Mediated Leukocyte Adhesion by SulfationScience, 1998
- Predominant pathogenic role of tumor necrosis factor in experimental colitis in miceEuropean Journal of Immunology, 1997
- Neopterin augmentation of tumor necrosis factor productionImmunology Letters, 1991
- Modulation of interleukin 2 high-affinity binding by lymphocyte-derived tetrahydrobiopterin: Pterins as potential participants in the control of interleukin 2 receptor assemblyJournal of Cellular Biochemistry, 1989